Corvus Pharmaceuticals, Inc.
$9.67-$0.34 (-3.4%)
Last close · Data as of Nov 20, 2026
- Market cap
- $985.5M
- P/E
- -64.5x
- EV / EBITDA
- -22.9x
- Revenue
- $0.00
- ROCE
- -69.6%
Price chart
Technical chartScreen technicals →This period includes a one-day price step on 20 Jan 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -5.5%
- 3M
- -32.5%
- 6M
- -20.7%
- 1Y
- Hidden
- 5Y
- Hidden
- This period includes a one-day price step on 20 Jan 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
52-week range
This period includes a one-day price step on 20 Jan 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
Day change -$0.34 (-3.4%) from $10.01 to $9.67 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in CRVS, bought on each weekday since 2021.
News & filings
What Corvus Pharmaceuticals filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 15.3 million US dollars in fiscal 2025.
Strengths (1)
- The company carries almost no debt: debt to equity of 0.02.
- Revenue is too small for margins and growth rates to be read, so those points are not shown.
- This period includes a one-day price step on 20 Jan 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
Read moreShow less
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
- Sector
- Healthcare
- Shares outstanding
- 74.7M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $985.5M
- P/E
- -64.5x
- P/B
- 16.1x
- EV / EBITDA
- -22.9x
- 52-week highThis period includes a one-day price step on 20 Jan 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
- Hidden
- 52-week lowThis period includes a one-day price step on 20 Jan 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
- Hidden
Profitability
- ROE
- -25.0%
- ROCE
- -69.6%
- ROIC
- -59.0%
- ROA
- -21.5%
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $0.00
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -75.5%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$33.0M
Solvency
- Current ratio
- 6.21
- Debt / Equity
- 0.02
- Debt / Assets
- 0.01
- CFO / Net profit
- 2.15
- Cash / Market cap
- 0.5%
Revenue and net profit
Annual revenue, with net profit as the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $0.00 | -$41.3M |
| FY2023 | $0.00 | -$27.0M |
| FY2024 | $0.00 | -$62.3M |
| FY2025 | $0.00 | -$15.3M |
Cash flows
FY2025: -$32.8M from operations, -$33.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$27.0M | -$27.3M |
| FY2023 | -$23.9M | -$24.0M |
| FY2024 | -$25.4M | -$25.4M |
| FY2025 | -$32.8M | -$33.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $0.00
- EBITDA
- -$42.9M
- Net profit
- -$15.3M
- Cash from operations
- -$32.8M
- Free cash flow
- -$33.0M
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $0.00 | -$42.9M | -$15.3M | -$33.0M | -25.0% | — | -75.5% |
Monthly returns
Month-by-month returns of CRVS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $71.1M |
| Current assets | $58.2M |
| Non-current assets | $12.9M |
| Liabilities | $9.9M |
| Current liabilities | $9.4M |
| Non-current liabilities | $530.0k |
| Equity | $61.2M |
| Paid-in capital | $474.4M |
| Retained earnings | -$412.3M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; CRVS highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Corvus Pharmaceuticals, Inc., Olema Pharmaceuticals, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc.CRVSthis company | $985.5M | -64.5x | 16.1x | -25.0% | -22.9x |
| QuidelOrtho CorporationQDEL | $1.0B | -0.9x | 0.5x | -58.9% | -7.7x |
| EyePoint, Inc.EYPT | $1.0B | -4.4x | 3.4x | -75.8% | -4.1x |
| Artivion, Inc.AORT | $1.0B | 103.7x | 2.3x | 2.2% | 18.9x |
| InnovAge Holding Corp.INNV | $977.3M | -32.2x | 4.2x | -12.9% | -102.4x |
| U.S. Physical Therapy, Inc.USPH | $940.1M | 62.4x | 2.0x | 3.2% | 11.1x |
| Anteris Technologies Global Corp.AVR | $939.4M | — | 48.7x | -238.4% | — |
| Olema Pharmaceuticals, Inc.OLMA | $932.9M | -5.7x | 1.9x | -33.9% | -5.0x |
| Nutex Health Inc.NUTX | $929.7M | 13.1x | 2.8x | 21.5% | 3.8x |
| Peer median | — | -0.9x | 2.5x | -23.4% | -4.1x |
Year-to-date ROI
CRVS since 1 January, against earlier years.
Historical volatility
CRVS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $0.00 |
| Operating expensesOperating Expense | $43.0M |
| Research and developmentResearch And Development | $33.7M |
| Selling, general and administrativeSelling General And Administration | $9.3M |
| Total expensesTotal Expenses | $43.0M |
| Operating incomeOperating Income | -$43.0M |
| Interest and other | |
| Pretax incomePretax Income | -$15.3M |
| Tax | |
| Net incomeNet Income | -$15.3M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $71.1M |
| Current assetsCurrent Assets | $58.2M |
| Non-current assetsTotal Non Current Assets | $12.9M |
| LiabilitiesTotal Liabilities Net Minority Interest | $9.9M |
| Current liabilitiesCurrent Liabilities | $9.4M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $530.0k |
| EquityTotal Equity Gross Minority Interest | $61.2M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$32.8M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$32.8M |
| Net income, continuing operationsNet Income From Continuing Operations | -$15.3M |
| Depreciation and amortisationDepreciation And Amortization | $100.0k |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $100.0k |
| Amortization of securitiesAmortization Of Securities | -$1.3M |
| Stock-based compensationStock Based Compensation | $5.3M |
| Operating gains and lossesOperating Gains Losses | -$25.2M |
| Gain loss on investment securitiesGain Loss On Investment Securities | -$27.1M |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $0.00 |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | $2.0M |
| Change in working capitalChange In Working Capital | $3.6M |
| Investing cash flowInvesting Cash Flow | -$7.8M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$7.8M |
| Capital expenditureCapital Expenditure | -$170.0k |
| Purchase of PP&EPurchase Of PPE | -$170.0k |
| Sale of PP&ESale Of PPE | $0.00 |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$170.0k |
| Purchase of investmentsPurchase Of Investment | -$91.8M |
| Sale of investmentsSale Of Investment | $84.1M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$7.6M |
| Financing cash flowFinancing Cash Flow | $36.4M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $36.4M |
| Shares issuedIssuance Of Capital Stock | $0.00 |
| Common stock issuedCommon Stock Issuance | $0.00 |
| Net common stock issuedNet Common Stock Issuance | $0.00 |
| Stock options exercisedProceeds From Stock Option Exercised | $36.4M |
| Change in cashChanges In Cash | -$4.2M |
| Cash at the start of the yearBeginning Cash Position | $8.7M |
| Cash at the end of the yearEnd Cash Position | $4.6M |
| Free cash flowFree Cash Flow | -$33.0M |
Learn while you research
Academy chapters picked for Corvus Pharmaceuticals, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read